Mining Gene Expression Signature for the Detection of Pre-Malignant Melanocytes and Early Melanomas with Risk for Metastasis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Souza, Camila Ferreira de ^a   Xander, Patrícia ^a   Monteiro, Ana Carolina ^a   Silva, Amanda Gonçalves dos Santos ^b   Silva, Débora Castanheira Pereira da ^b   Mai, Sabine ^c   Bernardo, Viviane ^a   Lopes, José Daniel ^a   Jasiulionis, Miriam Galvonas ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL STRUCTURE; CONTROLLED STUDY; CTCF GENE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; HSPB1 GENE; KARYOTYPE; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; NDRG2 GENE; NONHUMAN; NSD1 GENE; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; SERPINE1 GENE; SIGNAL TRANSDUCTION; SRC GENE; VDR GENE;

ANIMALS; AZACITIDINE; CELL LINE, TUMOR; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYDROXAMIC ACIDS; KARYOTYPING; MELANOCYTES; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RISK; SKIN NEOPLASMS;

MURINAE;

EID: 84866289919     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044800     Document Type: Article

References (61)

1. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
3. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, et al. (2011) A melanoma molecular disease model. PLoS One 6: e18257.
4. Souza CF, Morais AS, Jasiulionis MG, (2012) Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract pp. 156068.
5. Hoek KS, Goding CR, (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23: 746-759.
6. Jaenisch R, Bird A, (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 (Suppl) (): 245-254.
7. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102: 10604-10609.
8. Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor RE, et al. (2006) The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment. J Cell Mol Med 10: 174-196.
9. Utikal J, Maherali N, Kulalert W, Hochedlinger K, (2009) Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 122: 3502-3510.
10. Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, et al. (2009) Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics 1: 387-398.
11. Molognoni F, Cruz AT, Meliso FM, Morais AS, Souza CF, et al. (2011) Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics 6: 450-464.
12. Baylin SB, Jones PA, (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11: 726-734.
13. Szyf M, (2009) Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 49: 243-263.
14. Bennett DC, Cooper PJ, Hart IR, (1987) A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39: 414-418.
15. Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA, et al. (2006) Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 8: 231-241.
16. Roschke AV, Lababidi S, Tonon G, Gehlhaus KS, Bussey K, et al. (2005) Karyotypic "state" as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci USA 102: 2964-2969.
17. Silva AG, Graves HA, Guffei A, Ricca TI, Mortara RA, et al. (2010) Telomere-centromere-driven genomic instability contributes to Karyotype evolution in a mouse model of melanoma. Neoplasia 12: 11-19.
18. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, et al. (2005) Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26: 1856-1867.
19. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
20. Aldrian S, Trautinger F, Fröhlich I, Berger W, Micksche M, et al. (2002) Overexpression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro. Cell Stress Chaperones 7: 177-185.
21. Aldrian S, Kindas-Mügge I, Trautinger F, Fröhlich I, Gsur A, et al. (2003) Overexpression of Hsp27 in a human melanoma cell line: regulation of E-cadherin, MUC18/MCAM, and plasminogen activator (PA) system. Cell Stress Chaperones 8: 249-257.
22. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, et al. (2007) Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal-and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med (Berl) 85: 293-304.
23. Steele N, Finn P, Brown R, Plumb JA, (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100: 758-763.
24. Cedar H, Bergman Y, (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10: 295-304.
25. Mossman D, Scott RJ, (2011) Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation. PLoS ONE 6: e23127.
26. Ithychanda SS, Das M, Ma YQ, Ding K, Wang X, et al. (2009) Migfilin, a molecular switch in regulation of integrin activation. J Biol Chem 284: 4713-4722.
27. Kim A, Yang Y, Lee MS, Yoo YD, Lee HG, et al. (2008) NDRG2 gene expression in B16F10 melanoma cells restrains melanogenesis via inhibition of Mitf expression. Pigment Cell Melanoma Res 21: 653-664.
28. Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI, et al. (2009) Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 30: 927-936.
29. Slominski A, Tobin DJ, Shibahara S, Wortsman J, (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155-1228.
30. Brozyna AA, Jozwicki W, Janjetovic Z, Slominski AT, (2011) Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42: 618-631.
31. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, et al. (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 109: 2730-2735.
32. Meeran SM, Patel SN, Tollefsbol TO, (2010) Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS ONE 5: e11457.
33. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, et al. (2011) Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13: 1132-1142.
34. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
35. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
36. Slominski A, Wortsman J, (2000) Neuroendocrinology of the skin. Endocr Rev 21: 457-487.
37. Slominski A, (2009) Neuroendocrine activity of the melanocyte. Exp Dermatol 18: 760-763.
38. Nishimura EK, Suzuki M, Igras V, Du J, Lonning S, et al. (2010) Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell 6: 130-140.
39. Moriyama M, Osawa M, Mak SS, Ohtsuka T, Yamamoto N, et al. (2006) Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol 173: 333-339.
40. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing in adult cancers. Nat Genet 39: 237-242.
41. Lyon MF, (1962) Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet 14: 135-148.
42. Zhao J, Zhang Y, Ithychanda SS, Tu Y, Chen K, et al. (2009) Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. J Biol Chem 284: 34308-34320.
43. Kortlever RM, Higgins PJ, Bernards R, (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877-884.
44. Soto-Reyes E, Recillas-Targa F, (2010) Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene 29: 2217-2227.
45. Parker KA, Glaysher S, Polak M, Gabriel FG, Johnson P, et al. (2010) The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy. J Clin Pathol 63: 1012-1020.
46. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A chromatin-mediated reversible drug tolerant state in cancer cell subpopulations. Cell 141: 69-80.
47. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
48. Cheli Y, Guiliano S, Botton T, Rocchi S, Hofman V, et al. (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30: 2307-2318.
49. Ricca TI, Liang G, Suenaga AP, Han SW, Jones PA, et al. (2009) Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol 2: 329-340.
50. Montecino M, Stein GS, Cruzat F, Marcellini S, Stein JL, et al. (2007) An architectural perspective of vitamin D responsiveness. Arch Biochem Biophys 460: 293-299.
51. Do JT, Han DW, Gentile L, Sobek-Klocke I, Stehling M, et al. (2008) Enhanced reprogramming of Xist by induced upregulation of Tsix and Dnmt3a. Stem Cells 26: 2821-2831.
52. Navarro P, Chambers I, Karwacki-Neisius V, Chureau C, Morey C, et al. (2008) Molecular coupling of Xist regulation and pluripotency. Science 321: 1693-1695.
53. Escamilla-Del-Arenal M, da Rocha ST, Heard E, (2011) Evolutionary diversity and developmental regulation of X-chromosome inactivation. Hum Genet 130: 307-327.
54. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
55. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378.
56. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121.
57. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868.
58. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, et al. (2006) Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 34: W645-650.
59. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS, (2000) Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci USA 97: 12182-12186.
60. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365-371.
61. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.